Publication Details
Abstract
Diabetic retinopathy is still one of the major causes of visual loss among diabetic adults all around the world. This report assessed the clinical efficacy and safety of focal and panretinal argon laser photocoagulation in patients with different types of diabetic retinopathy. Information from recent clinical trials (2020-2025) was retrieved and analysed for the changes in visual acuity, macular thickness, and the number of complications or retreatment. The results show that the focal laser therapy is very efficient in reducing the diabetic macular oedema and improving the central vision, while the panretinal photocoagulation has a better long-term control of the proliferative disease (preventing the neovascularisation and the retinal detachment). Improved precision, decrease in retinal damage, and decreased time of the procedure with the use of newer technologies such as micropulse and navigated laser systems. Anti-VEGF combination regimens further enhanced the results and reduced the relapse rates. Overall, argon laser photocoagulation continues to be a vital element of evidence-based modern ophthalmologic practice, ensuring good stability of vision and disease progression in diabetic patients.